Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7952 results

Sort By:

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Study ID: NCT06224673
Start Date: 2025-04-15
End Date: 2028-07-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

36

Intervention / Treatment

Arch788

Computed Tomography (CT)

Biospecimen Collection

Amiloride

Sponsor

Laura Huppert, MD, BA

Source: clinicaltrials.gov

Share:
Add to list

Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)

Study ID: NCT05672927
Start Date: 2023-01-18
End Date: 2027-08
Study Type

Interventional

Study Phase

Phase4

No. of Participants

618

Intervention / Treatment

9-valent HPV vaccine, 2 doses alternate timing

9-valent HPV vaccine, 3 doses standard timing

Sponsor

The University of Texas Medical Branch, Galveston

Source: clinicaltrials.gov

Share:
Add to list

ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy

Study ID: NCT05318027
Start Date: 2023-05-22
End Date: 2025-12
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

70

Intervention / Treatment

ChatBot

Sponsor

Abramson Cancer Center at Penn Medicine

Source: clinicaltrials.gov

Share:
Add to list

64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)

Study ID: NCT05633160
Start Date: 2023-06-15
End Date: 2026-05
Study Type

Interventional

Study Phase

Phase2

No. of Participants

38

Intervention / Treatment

64CU-SAR-BBN

67Cu-SAR-BBN

Sponsor

Clarity Pharmaceuticals Ltd

Source: clinicaltrials.gov

Share:
Add to list

A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

Study ID: NCT06077760
Start Date: 2023-12-06
End Date: 2035-12-21
Study Type

Interventional

Study Phase

Phase3

No. of Participants

868

Intervention / Treatment

V940

Pembrolizumab

Placebo

Sponsor

Merck Sharp & Dohme LLC

Source: clinicaltrials.gov

Share:
Add to list

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Study ID: NCT05362773
Start Date: 2022-07-13
End Date: 2026-01
Study Type

Interventional

Study Phase

Phase1

No. of Participants

130

Intervention / Treatment

MGD024

Sponsor

Macrogenics

Source: clinicaltrials.gov

Share:
Add to list

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated with Brentuximab Vedotin or Checkpoint Inhibitors

Study ID: NCT05039073
Start Date: 2022-05-02
End Date: 2027-11-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

46

Intervention / Treatment

Bentuximab Vidotin

Hematopoietic Cell Transplantation

Nivolumab

Quality-of-Life Assessment

Administration questionnaire

Sponsor

Emory University

Source: clinicaltrials.gov

Share:
Add to list

Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

Study ID: NCT04069273
Start Date: 2020-12-01
End Date: 2025-12-10
Study Type

Interventional

Study Phase

Phase2

No. of Participants

58

Intervention / Treatment

Pembrolizumab Monotherapy

Ramsirumb

Paclitaxel

Sponsor

Harry H Yoon

Source: clinicaltrials.gov

Share:
Add to list

A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

Study ID: NCT06552260
Start Date: 2025-02-19
End Date: 2027-08-01
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

27

Intervention / Treatment

Trroriluzole

Sponsor

Eudocia Quant Lee, MD

Source: clinicaltrials.gov

Share:
Add to list

A Clinical Study of V940 and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

Study ID: NCT06833073
Start Date: 2025-03-11
End Date: 2031-09-03
Study Type

Interventional

Study Phase

Phase2

No. of Participants

308

Intervention / Treatment

V940

BCG

Sponsor

Merck Sharp & Dohme LLC

Source: clinicaltrials.gov

Share:
Add to list